We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+7.14%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.51B
AUM Growth
+$814M
Cap. Flow
+$783M
Cap. Flow %
17.35%
Top 10 Hldgs %
40.45%
Holding
134
New
22
Increased
42
Reduced
20
Closed
29

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$94.6M
2
AZN icon
AstraZeneca
AZN
+$82.2M
3
BAX icon
Baxter International
BAX
+$68.1M
4
CRBU icon
Caribou Biosciences
CRBU
+$60.5M
5
STVN icon
Stevanato
STVN
+$59.9M

Top Sells

Rank Stock Value
1
MRVI icon
Maravai LifeSciences
MRVI
+$124M
2
MDT icon
Medtronic
MDT
+$66.4M
3
BIIB icon
Biogen
BIIB
+$63.7M
4
NEO icon
NeoGenomics
NEO
+$61.7M
5
LLY icon
Eli Lilly
LLY
+$58.1M

Sector Composition

Rank Sector Weight
1 Healthcare 84.59%
2 Technology 0.99%
3 Financials 0.53%
4 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNAD
101
DELISTED
Social Capital Suvretta Holdings Corp. IV Class A Ordinary Shares
DNAD
$1.96M 0.04%
200,000
– –
PROK icon
102
ProKidney
PROK
$312M
$1.96M 0.04%
200,000
– –
NUVB.WS
103
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$253K 0.01%
99,999
– –
SLGCW
104
DELISTED
SomaLogic, Inc. Warrant
SLGCW
$228K 0.01%
+65,999
New +$203K
MSACW
105
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$41K ﹤0.01%
57,770
– –
ALDX icon
106
Aldeyra Therapeutics
ALDX
$94.7M
– –
-1,450,000
Closed -$16.4M
BBIO icon
107
BridgeBio Pharma
BBIO
$16.5B
– –
-673,400
Closed -$41M
BIIB icon
108
Biogen
BIIB
$31.2B
– –
-183,900
Closed -$63.7M
CAH icon
109
Cardinal Health
CAH
$54.4B
– –
-654,200
Closed -$37.3M
CELC icon
110
Celcuity
CELC
$3.96B
– –
-200,000
Closed -$4.8M
CFLT
111
DELISTED
Confluent
CFLT
– –
-100,000
Closed -$4.75M
CNC icon
112
Centene
CNC
$31B
– –
-751,200
Closed -$54.8M
CRDF icon
113
Cardiff Oncology
CRDF
$60.9M
– –
-1,395,000
Closed -$9.28M
DNLI icon
114
Denali Therapeutics
DNLI
$3.78B
– –
-86,100
Closed -$6.75M
DOCS icon
115
Doximity
DOCS
$3.91B
– –
-150,000
Closed -$8.73M
DVAX
116
DELISTED
Dynavax Technologies
DVAX
– –
-3,400,000
Closed -$33.5M
ESPR
117
DELISTED
Esperion Therapeutics
ESPR
– –
-400,000
Closed -$8.46M
FIGS icon
118
FIGS
FIGS
$1.8B
– –
-100,000
Closed -$5.01M
FLYW icon
119
Flywire
FLYW
$2.07B
– –
-50,000
Closed -$1.84M
MDT icon
120
Medtronic
MDT
$113B
– –
-535,000
Closed -$66.4M
MNDY icon
121
monday.com
MNDY
$3.82B
– –
-40,000
Closed -$8.94M
MRVI icon
122
Maravai LifeSciences
MRVI
$953M
– –
-2,963,545
Closed -$124M
NEO icon
123
NeoGenomics
NEO
$2.01B
– –
-1,367,000
Closed -$61.7M
NPCE icon
124
Neuropace
NPCE
$482M
– –
-40,000
Closed -$952K
PHVS icon
125
Pharvaris
PHVS
$2.28B
– –
-400,000
Closed -$7.45M
2 3 4
5
6

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q3 2021 Portfolio in Review

As of Q3 2021, Avidity Partners Management held 134 positions worth $4.51B, up 22% from $3.7B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Avidity Partners Management deployed $783M of net new capital in Q3 2021, opening 22 new positions and adding to 42 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 152,300 shares worth $92.2M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 95% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Eli Lilly, an estimated $58.1M trimmed.

  • Avidity Partners Management's largest Q3 2021 buy was Regeneron Pharmaceuticals: 152,300 shares worth $92.2M.
  • Avidity Partners Management added most to Mirati Therapeutics, Inc. Common Stock in Q3 2021, an estimated $49.8M increase.
  • Avidity Partners Management's biggest Q3 2021 reduction was Eli Lilly, cutting an estimated $58.1M.
  • Avidity Partners Management fully exited Maravai LifeSciences in Q3 2021, selling an estimated $124M.
  • Avidity Partners Management's ten largest holdings make up 40% of its $4.51B portfolio in Q3 2021.
  • Avidity Partners Management opened 22 new positions and closed 29 in Q3 2021.
  • Avidity Partners Management's portfolio value rose 22% quarter-over-quarter to $4.51B.

Based on Avidity Partners Management's 13F filing for Q3 2021, filed 15 Nov 2021.